Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Heliyon ; 10(13): e33485, 2024 Jul 15.
Artigo em Inglês | MEDLINE | ID: mdl-39040408

RESUMO

Utilizing computer-based scales for cognitive and psychological evaluations allows for the collection of objective data, such as response time. This cross-sectional study investigates the significance of response time data in cognitive and psychological measures, with a specific focus on its role in evaluating sleep quality through the Insomnia Severity Index (ISI) scale. A mobile application was designed to administer scale tests and collect response time data from 2729 participants. We explored the relationship between symptom severity and response time. A machine learning model was developed to predict the presence of insomnia symptoms in participants using response time data. The result revealed a statistically significant difference (p < 0.01) in the total response time between participants with or without insomnia symptom. Furthermore, a strong correlation was observed between the severity of specific insomnia aspects and the response times at the individual questions level. The machine learning model demonstrated a high predictive Area Under the ROC Curve (AUROC) of 0.824 in predicting insomnia symptoms based on response time data. These findings highlight the potential utility of response time data to evaluate cognitive and psychological measures.

2.
Chemotherapy ; 67(3): 123-131, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35134809

RESUMO

OBJECTIVE: The objective was to study the effectiveness and safety of super-selective bronchial arterial infusion (SBAI) chemotherapy in the treatment of advanced stage non-small cell lung cancer (NSCLC). METHODS: The clinical data of 120 advanced NSCLC patients were retrospectively analyzed. Among them, 60 NSCLC patients were treated with SBAI method, another 60 NSCLC patients received systemic intravenous chemotherapy as the control group. The efficacy and safety between two groups of patients were compared. RESULTS: The objective response rate and disease control rate of NSCLC patients treated with SBAI were significantly higher than those of the control group (p < 0.05). The 3-month progression-free survival (PFS) rate (96.67%) and 6-month PFS rate (86.67%) of the SBAI group were significantly higher than those of the control group (73.33% and 56.67%) (p < 0.01). After treatment, the FACT-L scores of patients in the SBAI group were significantly higher than those of the control group (p < 0.05). The scores of all the 13 core symptom items and six symptom interference items of NSCLC patients in the SBAI group were lower than those of the control group (p < 0.05). The adverse reactions rate in the SBAI group were significantly lower than those in the control group (p < 0.05). CONCLUSION: The short-term efficacy of SBAI chemotherapy for advanced NSCLC is significantly higher than that of traditional peripheral intravenous chemotherapy, and it can significantly improve patients' quality of life and reduce the incidence of adverse reactions.


Assuntos
Carcinoma Pulmonar de Células não Pequenas , Neoplasias Pulmonares , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Humanos , Neoplasias Pulmonares/tratamento farmacológico , Qualidade de Vida , Estudos Retrospectivos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA